PROTOBIOS OU

Their core work

Protobios is an Estonian biotech SME specializing in bioinformatics platforms for biomarker discovery and immune profiling. They develop computational and molecular diagnostic tools aimed at early detection of diseases, notably schizophrenia and autoimmune conditions. Their work spans from building bioinformatics analysis pipelines (ImmuneHunter) to contributing microfluidics-based real-time monitoring expertise in biomaterial safety assessment (PANBioRA). They sit at the intersection of data science and wet-lab diagnostics, translating complex immune response data into actionable clinical insights.

What they specialise in

How they've shifted over time

Protobios began with a clear focus on psychiatric and autoimmune diagnostics — their early projects (PROFILE, SZ_TEST) centered on schizophrenia biomarkers and immune-based patient stratification. By 2018, they pivoted toward broader biological safety applications, joining PANBioRA to apply their immune profiling expertise to biomaterial-tissue interactions, microfluidics, and toxicity testing. This shift suggests a deliberate move from niche disease diagnostics toward platform-level immune monitoring applicable across multiple domains.

Protobios is broadening from disease-specific biomarker work toward generalized immune response monitoring platforms, making them increasingly relevant for biomaterials, drug safety, and personalized medicine applications.

How they like to work

Protobios operates as both a project initiator and a contributing specialist. They coordinated two smaller projects (SZ_TEST and the SME Phase 1 ImmuneHunter) while joining larger research consortia as a participant, including PANBioRA where they received their largest single grant. With 37 unique partners across 14 countries from just 4 projects, they demonstrate a wide-reaching collaborative network rather than a closed circle of repeat partners.

Despite being a small Estonian company, Protobios has built a network of 37 partners across 14 countries through just 4 projects, indicating strong integration into European research consortia. Their partnerships span training networks (MSCA) and large multi-partner research actions.

What sets them apart

Protobios occupies a rare niche as an SME that bridges bioinformatics and wet-lab immune profiling — most small biotech companies specialize in one or the other. Their combination of computational platform development (ImmuneHunter) with hands-on biomarker and toxicity work (PANBioRA, SZ_TEST) means they can contribute both data analysis and experimental capabilities to a consortium. For an Estonian SME, their reach across 14 countries and ability to secure both SME Instrument and RIA funding demonstrates unusual credibility in the EU research ecosystem.

Highlights from their portfolio

• PANBioRA
  Their largest funded project (EUR 461,250) and a significant pivot — applying immune profiling expertise to biomaterial safety, expanding their portfolio beyond disease diagnostics.
• SZ_TEST
  Coordinated by Protobios, this project targeted early molecular diagnostics of schizophrenia — a high-impact clinical challenge combining their core biomarker and bioinformatics strengths.
• ImmuneHunter
  An SME Phase 1 project where Protobios pitched their own bioinformatics platform for multi-disease profiling, demonstrating commercial ambition beyond pure research.